These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36897550)

  • 1. Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe.
    Henshall CH; Dankó D; Barham L; Espín J; Felix J; Harney M; Indra P; Mestre-Ferrandiz J; de Pouvourville G; Spandonaro F; Vončina L; Wilking N
    Appl Health Econ Health Policy; 2023 Jul; 21(4):537-546. PubMed ID: 36897550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
    Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
    Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 6. Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping.
    van Kessel R; Srivastava D; Kyriopoulos I; Monti G; Novillo-Ortiz D; Milman R; Zhang-Czabanowski WW; Nasi G; Stern AD; Wharton G; Mossialos E
    JMIR Mhealth Uhealth; 2023 Sep; 11():e49003. PubMed ID: 37773610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.
    Sabatini MT; Xia T; Chalmers M
    Pharmaceut Med; 2022 Oct; 36(5):265-274. PubMed ID: 35994198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology.
    Dankó D; Blay JY; Garrison LP
    Health Policy; 2019 Dec; 123(12):1230-1236. PubMed ID: 31337514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
    Godman B; Hill A; Simoens S; Selke G; Selke Krulichová I; Zampirolli Dias C; Martin AP; Oortwijn W; Timoney A; Gustafsson LL; Voncina L; Kwon HY; Gulbinovic J; Gotham D; Wale J; Cristina Da Silva W; Bochenek T; Allocati E; Kurdi A; Ogunleye OO; Meyer JC; Hoxha I; Malaj A; Hierländer C; Sauermann R; Hamelinck W; Petrova G; Laius O; Langner I; Yfantopoulos J; Joppi R; Jakupi A; Greiciute-Kuprijanov I; Vella Bonanno P; Piepenbrink JH; de Valk V; Wladysiuk M; Marković-Peković V; Mardare I; Fürst J; Tomek D; Obach Cortadellas M; Zara C; Pontes C; McTaggart S; Laba TL; Melien Ø; Wong-Rieger D; Bae S; Hill R
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):527-540. PubMed ID: 33535841
    [No Abstract]   [Full Text] [Related]  

  • 11. "Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.
    Vogler S
    Ger Med Sci; 2022; 20():Doc05. PubMed ID: 35465640
    [No Abstract]   [Full Text] [Related]  

  • 12. Accelerating patient access to oncology medicines with multiple indications in Europe.
    Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
    J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
    [No Abstract]   [Full Text] [Related]  

  • 13. Market access pathways for cell therapies in France.
    Rémuzat C; Toumi M; Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
    Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
    Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.
    Latimer NR; Pollard D; Towse A; Henshall C; Sansom L; Ward RL; Bruce A; Deakin C
    BMC Health Serv Res; 2021 May; 21(1):412. PubMed ID: 33941174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of generic drug prices in seven European countries: a methodological analysis.
    Wouters OJ; Kanavos PG
    BMC Health Serv Res; 2017 Mar; 17(1):242. PubMed ID: 28359273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.
    Vancoppenolle JM; Koole SN; O'Mahony JF; Franzen N; Burgers JA; Retèl VP; van Harten WH
    Drug Discov Today; 2023 Aug; 28(8):103620. PubMed ID: 37201780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
    Preckler V; Espín J
    Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.